Nuevo número de la revista AIDS
Disponible en línea el número 7 del volumen 25, correspondiente al 24 abril del 2011, de la revista AIDS.
Editorial Review
HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
Concise Communications
The natural history of liver cirrhosis in HIV–hepatitis C virus-coinfected patients
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala
Clinical Science
Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis
Peripheral neuropathy in HIV: prevalence and risk factors
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection
Concise Communication
Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy
Epidemiology and Social
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women
Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV–hepatitis C virus co-infection
Trends in unsafe sex and influence of viral load among patients followed since primary HIV infection, 2000–2009
Ignoring the group in group-level HIV/AIDS intervention trials: a review of reported design and analytic methods
Editorial Comment
Resistance, resistance, go away: persistence of nevirapine-resistant HIV mutations in HIV-infected infants
Research Letters
The rise and fall of methicillin-resistant Staphylococcus aureus infections in HIV patients
Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?
The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score
Correspondence
Reply to comment on ‘pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’
Reply to ‘Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’
New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B
Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents
Esta publicación está disponible para los usuarios de la red de salud a través de Hinari.
